Physician

Stephen J. Pollard, M.D.

According to 2025 Medicare claims, Stephen Pollard, M.D. (NPI: 1629077698) practices allergy/immunology in the Elizabethtown, KY market, with the plurality of this provider's patient population coming from Hardin, KY. This provider's primary affiliated billing organization is PSF PLLC (NPI: 1881785947; TIN: 611389493) and primary practice location at 40223-2992.

Pollard's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 524 traditional Medicare patients, billed 42,051 HCPCS/CPT codes, and received $549,707 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,848 prescription claims across 471 beneficiaries totaling $614,259 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 36 claims. Open Payments data shows 84 records totaling $57,255. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $117,098 to $549,707. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $271,398 to $614,259. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,140 and ending at $1,343.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	624	13,582	$117,098
2016	734	16,816	$144,722
2017	843	18,080	$205,380
2018	883	17,394	$151,955
2019	1,068	21,760	$204,037
2020	931	23,284	$301,313
2021	1,057	24,642	$312,846
2022	983	24,743	$297,941
2023	501	34,708	$472,886
2024	524	42,051	$549,707

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	289	1,872	$271,398
2016	307	2,025	$313,209
2017	345	2,482	$372,646
2018	348	2,619	$440,005
2019	365	2,563	$501,254
2020	369	2,556	$602,299
2021	404	2,610	$1,044,518
2022	424	2,729	$881,073
2023	434	2,748	$688,241
2024	471	2,848	$614,259

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	23	$186
2016	N/R	37	$1,326
2017	N/R	33	$628
2018	N/R	85	$45,795
2019	12	110	$2,703
2020	N/R	113	$2,138
2021	N/R	101	$58,773
2022	N/R	96	$61,127
2023	N/R	39	$64,466
2024	N/R	36	$60,029

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	222	290	$60
95012	Test to measure the level of nitric oxide gas	179	248	$12
95165	Professional service for preparation and provision of 1 or more antigens	322	8,500	$9
95117	Professional service for multiple injections of allergen	357	7,210	$8
96160	Administration and interpretation of patient-focused health risk assessment	236	310	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	107	4,500	$91,819
Dupixent Syringe	Dupilumab	22	672	$89,453
Spiriva Respimat	Tiotropium Bromide	115	4,050	$68,029
Dupixent Pen	Dupilumab	15	420	$55,424
Advair Hfa	Fluticasone Propion/Salmeterol	53	2,010	$23,691

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	12	$58,905
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	12	$908
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	12	$216

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	54	$39,312	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	30	$17,943	Regeneron Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephen J. Pollard, M.D.?

Tedicare shows public-source Medicare data for Stephen J. Pollard, M.D. (NPI 1629077698), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen J. Pollard, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stephen J. Pollard, M.D.?

Stephen J. Pollard, M.D. is linked to PSF PLLC (billing NPI 1881785947) in the available physician profile data.

Does Stephen J. Pollard, M.D. have Open Payments data?

Stephen J. Pollard, M.D. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.